Healthy Bill

healthybill.net

Healthy Bill is the one stop shop for all your healthcare needs, providing access to inexpensive Diagnostic centers, Pharmacies, Hospitals and Wellness centers. Our mission is to make health care services accessible and affordable to everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

news image

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

news image

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More

Regulatory

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

news image

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

news image

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More
news image

Cell and Gene Therapy

IMARA ANNOUNCES PRIMARY ENDPOINT CHANGE IN THE ARDENT PHASE 2B CLINICAL TRIAL OF TOVINONTRINE (IMR-687) IN SICKLE CELL DISEASE

Imara | November 22, 2021

Imara Inc. a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced a change to the primary endpoint for the Ardent clinical trial, a Phase 2b study of tovinontrine (IMR-687) in patients with sickle cell disease (SCD), based on the recommendation of the U.S. Food and Drug Administration (FDA). Imara requested f...

Read More
news image

CURIS ANNOUNCES $30 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC

BioSpace | February 27, 2020

Curis, Inc. a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a common stock purchase agreement (the "Agreement") of up to $30 million with Aspire Capital Fund, LLC ("Aspire Capital"). Under the terms of the Agreement, Aspire Capital has made an initial investment of $3 million via purchase of 2,693,965 common shares of Curis. In addition, Aspire Capital has committed to purchasi...

Read More
news image

Regulatory

LUMMUS AND BRASKEM ANNOUNCE PARTNERSHIP FOR GREEN ETHYLENE TECHNOLOGY

Braskem | April 29, 2022

Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...

Read More
news image

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us